EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer

التفاصيل البيبلوغرافية
العنوان: EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer
المؤلفون: Weifeng Song, Feng Jiao, Liwei Wang, Lei Wang, Ting Han, Cuncun Yuan, Hai Hu, Ziliang Jin
المصدر: Oncotarget
بيانات النشر: Impact Journals LLC, 2016.
سنة النشر: 2016
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Pathology, medicine.medical_specialty, cell migration, pancreatic cancer, enhancer of zeste homolog 2, macromolecular substances, Kaplan-Meier Estimate, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Antigens, CD, Cell Movement, Pancreatic cancer, medicine, Gene silencing, Humans, Enhancer of Zeste Homolog 2 Protein, Neoplasm Invasiveness, Aged, Cell Proliferation, Gene knockdown, long non-coding RNA, Cell growth, business.industry, EZH2, Cancer, Middle Aged, medicine.disease, Cadherins, metastasis associated lung adenocarcinoma transcript 1, Gene Expression Regulation, Neoplastic, Pancreatic Neoplasms, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, Adenocarcinoma, Female, RNA, Long Noncoding, business, Research Paper
الوصف: Enhancer of zeste homolog 2 (EZH2) is an essential component of the polycomb repressive complex 2 (PRC2), which is required for epigenetic silencing of target genes, including those affecting cancer progression. Its role in pancreatic cancer remains to be clarified; therefore, we investigated the effects of aberrantly expressed EZH2 on pancreatic cancer. We found that EZH2 expression is up-regulated in pancreatic cancer tissues and positively correlated with lymph node metastasis and advanced clinical stage in pancreatic cancer patients. EZH2 knockdown in pancreatic cancer cell lines inhibited cell migration and invasion, but did not alter cell proliferation. Silencing of EZH2 also increased E-cadherin expression in vitro, and E-cadherin expression was inversely correlated with EZH2 expression in pancreatic cancer tissue samples. Patients with high EZH2 and low E-cadherin expression had the worst prognosis. RIP and ChIP assays suggest that EZH2 is recruited to the E-cadherin promoter by the long non-coding RNA, MALAT-1 (metastasis associated in lung adenocarcinoma transcript 1), where it represses E-cadherin expression. Our results show that EZH2-based therapies may be an option for the treatment of pancreatic cancer.
اللغة: English
تدمد: 1949-2553
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8b579ff2f7f4eb649def047aeedc6fTest
http://europepmc.org/articles/PMC4905466Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....ee8b579ff2f7f4eb649def047aeedc6f
قاعدة البيانات: OpenAIRE